2021-04-28 16:00Financial Performance - The company's revenue for Q1 2021 was ¥1,267,876,796.45, a decrease of 9.59% compared to ¥1,402,313,084.20 in the same period last year[8]. - Net profit attributable to shareholders was ¥143,483,266.73, down 43.80% from ¥255,292,717.45 year-on-year[8]. - The net profit after deducting non-recurring gains and losses was ¥114,511,999.79, a decline of 59.50% compared to ¥282,711,693.79 in the previous year[8]. - Basic and diluted earnings per share were both ¥0.0978, representing a decrease of 52.22% from ¥0.2047 in the previous year[8]. - The company's operating revenue for the reporting period was ¥1,267,876,796.45, a decrease of 9.59% compared to the same period last year[21]. - The net profit for the reporting period was ¥142,677,904.44, reflecting a decline of 43.97% year-on-year[24]. - The company's gross profit margin decreased, leading to a 40.24% drop in operating profit to ¥182,256,245.68[24]. - The investment income fell by 49.04% to ¥32,393,930.46, due to reduced net profits from joint ventures[21]. - The company reported a total comprehensive income of ¥150,660,916.07 for the current period, down from ¥305,679,607.31 in the previous period[84]. Cash Flow and Liquidity - The net cash flow from operating activities increased by 292.52%, reaching ¥419,806,687.16, compared to a negative cash flow of ¥218,059,075.62 in the same period last year[8]. - The cash flow from operating activities increased significantly by 292.52% to ¥419,806,687.16, driven by higher cash receipts from sales[24]. - The net increase in cash and cash equivalents was ¥769,379,717.55, a significant rise of 1665.53% compared to the previous year[24]. - The total cash and cash equivalents at the end of the period reached CNY 2,099,624,973.72, an increase from CNY 1,027,391,896.32 at the end of Q1 2020[98]. - The company reported a decrease in cash outflow for purchasing goods and services to CNY 889,665,267.98 from CNY 968,530,906.95 in the previous year[94]. - The net cash flow from operating activities was -322,751,475.95 CNY, an improvement from -935,732,615.84 CNY in the previous period[99]. - The total cash inflow from investment activities was 1,341,828,219.38 CNY, significantly up from 417,597,356.30 CNY in the prior period[101]. - The company reported a net increase in cash and cash equivalents of 569,389,517.60 CNY, contrasting with a decrease of -34,511,187.68 CNY in the previous period[101]. Assets and Liabilities - Total assets at the end of the reporting period were ¥19,391,183,967.54, an increase of 1.92% from ¥19,025,894,654.11 at the end of the previous year[8]. - The total assets decreased by 48.58% in accounts receivable, amounting to ¥18,011,692.30, due to timely collections[21]. - The company's accounts payable increased by 33.79% to ¥320,038,385.70, primarily due to higher raw material procurement costs[21]. - Total liabilities increased from ¥7,336,904,566.95 to ¥7,552,576,728.95, an increase of approximately 2.9%[63]. - Total current liabilities decreased slightly from ¥3,612,834,053.85 to ¥3,681,622,063.90, an increase of approximately 1.9%[63]. - Long-term borrowings increased from ¥1,533,623,523.10 to ¥1,647,855,134.47, an increase of about 7.5%[63]. - Total current assets reached CNY 10,245,386,524.19, compared to CNY 9,128,707,884.99 at the end of 2020, indicating a growth of approximately 12.3%[57]. - Total non-current assets decreased from ¥9,897,186,769.12 to ¥9,145,797,443.35, a reduction of about 7.6%[60]. Investments and Subsidiaries - The company approved an investment of $60 million in TPG Biotechnology Partners V, L.P. on June 16, 2016, which is ongoing[25]. - An additional investment of $55 million in its wholly-owned subsidiary Hepalink (Hong Kong) Co., Ltd. was approved on September 20, 2016, and is still pending completion[25]. - The company plans to increase its investment in Hepalink USA Inc. by approximately RMB 500 million, with a previous investment of $11.29 million approved on July 31, 2020, which remains incomplete[25]. - The company decided to invest $20 million in ORI Healthcare Fund, L.P. on January 22, 2016, with an additional $20 million approved on September 20, 2016, and this investment is ongoing[25]. - The transfer of Kymab Group Limited shares to Sanofi Foreign Participations BV was completed in April 2021, with the company receiving the first installment of the transfer price[29]. - The company has not completed the final delivery of the asset transaction for its subsidiary, which was approved on April 20, 2020[25]. Shareholder and Governance - The total number of ordinary shareholders at the end of the reporting period was 35,084, with the top ten shareholders holding a combined 82.06% of the shares[12]. - The company has committed to not engage in any competing business during the period of being a controlling shareholder, which has been strictly adhered to[32]. - The company has fulfilled all commitments made to minority shareholders in a timely manner[38]. - The company has made commitments regarding tax reimbursements and has agreed to return any additional taxes and related costs incurred due to tax authority actions[35]. - The company has not implemented any share repurchase plans during the reporting period[29]. Research and Development - Research and development expenses for the current period are ¥17,792,316.55, slightly up from ¥17,748,891.89 in the previous period[78].